The Latest SPAC News and Rumors: January 3, 2022


The Latest SPAC News and Rumors: January 3, 2022

Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News:  Securities Commission Malaysia revision could revive more SPACs; Alpha Tau completes enrollment of Japanese pivotal clinical trial

SC’s Revision Could Revive More SPACs in Malaysia

The revised equity guidelines for the enhanced SPAC framework from Jan 1, 2022 are expected to make the asset class a more attractive option for promoters and potential investors. 

The revisions announced by the Securities Commission Malaysia (SC) last December provide more management flexibility to SPACs, allowing professionals with extensive experience in private equity and venture capital with asset sourcing and deal making experience to steer SPACs, said Dr Liew Chee Yoong, Assistant Professor of Finance at UCSI University and a Fellow of the Centre for Market Education. 


Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer

Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has been notified by HekaBio K.K., its clinical trial partner in Japan, that recruitment has been completed in its open-label multi-center pivotal study evaluating the Alpha DaRT in Japanese patients with recurrent Head & Neck cancer after radiotherapy.

HekaBio has reported that preliminary results of this trial are highly encouraging, and that it will continue compilation and analysis of the data in collaboration with its medical experts, in an effort to prepare a submission seeking marketing approval via the shonin pathway in consultation with Japanese authorities.

On July 8, 2021, Alpha Tau announced that it had entered into a definitive merger agreement with Healthcare Capital Corp. (Nasdaq: HCCC).